Literature DB >> 20613512

Advances in Rift Valley fever research: insights for disease prevention.

A Desiree LaBeaud1, James W Kazura, Charles H King.   

Abstract

PURPOSE OF REVIEW: The purpose was to review recent research on Rift Valley fever virus (RVFV) infection, encompassing four main areas: epidemiology and outbreak prediction, viral pathogenesis, human diagnostics and therapeutics, and vaccine and therapeutic candidates. RECENT
FINDINGS: RVFV continues to extend its range in Africa and the Middle East. Better definition of RVFV-related clinical syndromes and human risk factors for severe disease, combined with early-warning systems based on remote-sensing, simplified rapid diagnostics, and tele-epidemiology, hold promise for earlier deployment of effective outbreak control measures. Advances in understanding of viral replication pathways and host cell-related pathogenesis suggest means for antiviral therapeutics and for more effective vaccination strategies based on genetically engineered virus strains or subunit vaccines.
SUMMARY: RVFV is a significant health and economic burden in many areas of Africa, and remains a serious threat to other parts of the world. Development of more effective methods for RVFV outbreak prevention and control remains a global health priority.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20613512      PMCID: PMC3126654          DOI: 10.1097/QCO.0b013e32833c3da6

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  45 in total

1.  Development and evaluation of a real-time reverse transcription-loop-mediated isothermal amplification assay for rapid detection of Rift Valley fever virus in clinical specimens.

Authors:  C A Le Roux; T Kubo; A A Grobbelaar; P Jansen van Vuren; J Weyer; L H Nel; R Swanepoel; K Morita; J T Paweska
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

2.  Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs.

Authors:  M Bouloy; C Janzen; P Vialat; H Khun; J Pavlovic; M Huerre; O Haller
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Severe Rift Valley fever may present with a characteristic clinical syndrome.

Authors:  Summerpal S Kahlon; Clarence J Peters; James Leduc; Eric M Muchiri; Samuel Muiruri; M Kariuki Njenga; Robert F Breiman; A Clinton White; Charles H King
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

Review 4.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  An outbreak of Rift Valley fever in Northeastern Kenya, 1997-98.

Authors:  Christopher W Woods; Adam M Karpati; Thomas Grein; Noel McCarthy; Peter Gaturuku; Eric Muchiri; Lee Dunster; Alden Henderson; Ali S Khan; Robert Swanepoel; Isabelle Bonmarin; Louise Martin; Philip Mann; Bonnie L Smoak; Michael Ryan; Thomas G Ksiazek; Ray R Arthur; Andre Ndikuyeze; Naphtali N Agata; Clarence J Peters
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

6.  Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses.

Authors:  Matthias Habjan; Nicola Penski; Valentina Wagner; Martin Spiegel; Anna K Overby; Georg Kochs; Juha T Huiskonen; Friedemann Weber
Journal:  Virology       Date:  2009-01-19       Impact factor: 3.616

7.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

8.  Climate impacts on environmental risks evaluated from space: a conceptual approach to the case of Rift Valley Fever in Senegal.

Authors:  Yves M Tourre; Jean-Pierre Lacaux; Cécile Vignolles; Murielle Lafaye
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

9.  Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.

Authors:  Nina Lagerqvist; Jonas Näslund; Ake Lundkvist; Michèle Bouloy; Clas Ahlm; Göran Bucht
Journal:  Virol J       Date:  2009-01-17       Impact factor: 4.099

10.  Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases.

Authors:  M Melina Soares; Steven W King; Philip E Thorpe
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

View more
  16 in total

1.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

2.  Translating Predictions of Zoonotic Viruses for Policymakers.

Authors:  Seth D Judson; Matthew LeBreton; Trevon Fuller; Risa M Hoffman; Kevin Njabo; Timothy F Brewer; Elsa Dibongue; Joseph Diffo; Jean-Marc Feussom Kameni; Severin Loul; Godwin W Nchinda; Richard Njouom; Julius Nwobegahay; Jean Michel Takuo; Judith N Torimiro; Abel Wade; Thomas B Smith
Journal:  Ecohealth       Date:  2017-12-11       Impact factor: 3.184

3.  Characterization of wild-type and alternate transcription termination signals in the Rift Valley fever virus genome.

Authors:  Estelle Lara; Agnès Billecocq; Psylvia Leger; Michèle Bouloy
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

4.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

5.  Environmental limits of Rift Valley fever revealed using ecoepidemiological mechanistic models.

Authors:  Giovanni Lo Iacono; Andrew A Cunningham; Bernard Bett; Delia Grace; David W Redding; James L N Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-18       Impact factor: 11.205

6.  Curcumin inhibits Rift Valley fever virus replication in human cells.

Authors:  Aarthi Narayanan; Kylene Kehn-Hall; Svetlana Senina; Lindsay Lundberg; Rachel Van Duyne; Irene Guendel; Ravi Das; Alan Baer; Laura Bethel; Michael Turell; Amy Lynn Hartman; Bhaskar Das; Charles Bailey; Fatah Kashanchi
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

Review 7.  The 2007 Rift Valley fever outbreak in Sudan.

Authors:  Osama Ahmed Hassan; Clas Ahlm; Rosemary Sang; Magnus Evander
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

8.  Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection.

Authors:  Aarthi Narayanan; Taissia Popova; Michael Turell; Jessica Kidd; Jessica Chertow; Serguei G Popov; Charles Bailey; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 9.  Towards a better understanding of Rift Valley fever epidemiology in the south-west of the Indian Ocean.

Authors:  Thomas Balenghien; Eric Cardinale; Véronique Chevalier; Nohal Elissa; Anna-Bella Failloux; Thiery Nirina Jean Jose Nipomichene; Gaelle Nicolas; Vincent Michel Rakotoharinome; Matthieu Roger; Betty Zumbo
Journal:  Vet Res       Date:  2013-09-09       Impact factor: 3.683

10.  Rift Valley fever risk map model and seroprevalence in selected wild ungulates and camels from Kenya.

Authors:  Seth C Britch; Yatinder S Binepal; Mark G Ruder; Henry M Kariithi; Kenneth J Linthicum; Assaf Anyamba; Jennifer L Small; Compton J Tucker; Leonard O Ateya; Abuu A Oriko; Stephen Gacheru; William C Wilson
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.